Abbott Laboratories stock drops about 1.5% after negative momentum signals and moving average breaks

Traders Union
All News
Stocks
Abbott Laboratories slides 1.48% today

Highlights

Abbott Laboratories reported Q2 2026 revenue of $12.593 billion, up 13%, with adjusted EPS at $1.31.
The company increased its quarterly dividend for the 54th consecutive year and introduced its FDA-approved SimpleScreen CRC blood test.
Shares of Abbott Laboratories closed at $99.46 after a 1.48% decline, trading below key moving averages with momentum indicators reading oversold; the expected five-day range is $97.09 to $102.07.

Dividend streak and product launches fail to offset persistent selloff

Abbott Laboratories increased its quarterly dividend for the 54th consecutive year and declared its 411th straight quarterly payout. The company reported a 13% increase in Q2 2026 revenue to $12.593 billion, with adjusted EPS reaching $1.31. Abbott also launched its FDA-approved SimpleScreen CRC blood test for colorectal cancer screening in adults aged 45 and older. Its Q3 2026 earnings call is scheduled for October 21, 2026, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent selling pressure as a major red flag for Abbott Laboratories. The break below all key moving averages and deepening negative momentum signal that sellers have firm control. Despite the long dividend track record and strong revenue growth, Kharitonov remains unconvinced by the current setup. Technical signals like the MACD, ADX, and RSI cluster in bearish territory, underlining the fragility of short-term price action. Risk skew is clearly negative — any bounce toward $99.48 faces strong resistance. "I see more downside risk here than opportunity; the technicals warrant caution until the momentum shifts meaningfully."

Viktoras Karapetjanc, expert at Traders Union, focuses on Abbott Laboratories' resilient fundamentals. He believes enduring dividend growth and robust revenue gains set a strong base for investor confidence, despite recent price weakness. The FDA-cleared rollout of SimpleScreen CRC expands growth potential in key health markets. Karapetjanc remains constructive, noting that sideways price action creates favorable entry setups for patient investors. "With solid financials and new product momentum, I expect further growth once near-term selling pressure abates."

Parshwa Turakhiya, analyst, points to distinctly oversold readings across momentum oscillators for Abbott Laboratories. He sees current sentiment as shaken but not broken, with the volatility range between $97.09 and $102.07 suggesting tactical trading opportunities. Short-term bounces are possible, especially if support at $97.09 holds. Yet the setup remains scenario-driven with clear risk of breakdown if selling intensifies. "I'm watching for intraday reversals and sentiment shifts — aggressive traders can exploit the current oversold state, but capital protection is key."

Oversold signals intensify as ABT breaches major technical levels

ABT is trading below its 20-day ($103.97), 50-day ($107), and 200-day ($104.43) moving averages, highlighting persistent selling pressure across all timeframes. For immediate trading, $99.48 marks a near-term ceiling while $97.09 forms the nearest support. Momentum is decisively negative: both the MACD and ADX signal selling. The RSI sits at 34.86, the CCI at -98.81, and the Stochastic RSI at 14.67, signaling clear oversold conditions. Bear/Bull Power is negative at -1.9, and the Awesome Oscillator confirms the downside bias. The overall tone remains pressured, with price and momentum both aligned on the downside.

Earlier, analysts noted that Abbott Laboratories was experiencing sustained downward momentum amid persistent selling pressure and technical weakness. The current article reinforces this bearish outlook, with new oversold signals and negative momentum suggesting traders should focus on the $97.09 support as a key level for potential downside risk in the near term.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.